GHRP-6
A synthetic hexapeptide (His-DTrp-Ala-Trp-DPhe-Lys-NH2) and one of the earliest ghrelin receptor (GHS-R1a) agonists to be characterised; because it shares its receptor with ghrelin, it stimulates growth hormone release while also increasing appetite. Reportedly investigated for GH stimulation, muscle anabolism, and GI protective effects; community use focuses primarily on GH secretion. Human pharmacodynamic studies confirm reliable GH pulse amplification; controlled trials examining therapeutic endpoints such as body composition have not been published.
Side effects & risks
GHRP-6 has not been evaluated in large-scale, randomised controlled trials for therapeutic use in healthy adults. The risk profile in that context is, in practical terms, unknown.
The most consistently reported subjective effect in GHRP-6 research subjects is a substantial, transient increase in appetite. This is a direct pharmacological consequence of GHS-R1a activation — the same receptor through which endogenous ghrelin drives pre-meal appetite, as characterised in the foundational ghrelin pharmacology literature (Wren et al., 2001, Journal of Clinical Endocrinology and Metabolism; PMID 11739476). The appetite-stimulating property is intrinsic to GHS-R1a agonism and distinguishes GHRP-6 from more selective secretagogues such as ipamorelin. No dedicated peer-reviewed clinical trial has formally assessed GHRP-6-specific food intake as a primary endpoint in human subjects.
A second documented physiological consequence is transient elevation of cortisol and prolactin, documented in multiple human pharmacokinetic investigations, including Cabrales et al. (2013, European Journal of Pharmaceutical Sciences; PMID 23099431) who specifically measured cortisol and ACTH responses alongside GH in healthy volunteers. The clinical significance of repeated cortisol pulses from sustained GHRP-6 administration in community protocols has not been characterised.
Hypoglycaemia risk is a theoretical concern because GH stimulation can transiently affect insulin sensitivity. This concern is amplified by GHRP-6's ghrelin-mimetic mechanism, which independently influences glucose homeostasis. This interaction has not been formally characterised for community-reported subcutaneous administration regimens.
A theoretical concern shared with all growth hormone secretagogues is the potential for IGF-1-mediated effects over extended administration, which has been associated epidemiologically with cancer risk. The causal relationship and the magnitude of any risk from GHRP-6's transient GH stimulation are not established in peer-reviewed literature.
Injection-site reactions (redness, transient pain) are reported in community accounts and are consistent with subcutaneous peptide administration generally.
GHRP-6 is not approved for human therapeutic use in any major regulatory jurisdiction. Individuals obtaining it as a research chemical assume an undetermined risk profile.
Evidence summary
Latest studies
Phase III Open-Label, Randomized Clinical Trial of Epidermal Growth Factor and Growth Hormone Releasing Hexapeptide in Acute Ischemic Stroke.
In this phase III open-label trial, combined epidermal growth factor and GHRP-6 for acute ischemic stroke did not improve overall disability at six months, though a pre-specified severe-stroke subgroup showed reduced disability and mortality.
EGF and GHRP6 Co-Administration Attenuates Cognitive Decline in Preclinical Models: Behavioral and Molecular Evidences.
This is an animal study in mice looking at whether combining two compounds, a growth factor called EGF and the peptide GHRP-6, could help with cognitive decline. Researchers used two mouse models: normal aging, and memory impairment triggered by a chemical injected into the brain. Groups of 14 to 15 mice were tested on walking patterns and memory tasks. Mice given the EGF plus GHRP-6 combination walked with longer steps and did better on memory tests than untreated mice. The treatment also shifted the activity of several genes in a direction linked to reduced oxidative stress, better connections between brain cells, and healthier support cells, while lowering a gene tied to inflammation. Because this was done in mice and the two compounds were given together, the study cannot show how much GHRP-6 contributed on its own, and results in animals often do not carry over to people. The authors describe it as a promising direction that needs much more research before any human use.
A discovery-based proteomic approach of epidermal growth factor and growth hormone-releasing peptide-6 in a model of acute ischemic stroke.
This study explored how a two-drug combination — epidermal growth factor (EGF) plus GHRP-6 — might protect the brain after a stroke, using rats whose middle cerebral artery was blocked. Researchers analyzed thousands of proteins in the at-risk brain tissue (the 'penumbra') at 3 and 24 hours after treatment. The combination was associated with changes in dozens to hundreds of proteins, including consistent effects on proteins that move brain chemical messengers, and, by 24 hours, on proteins that mop up damaging molecules, resist cell death, and manage low-oxygen stress. Proteins known to reduce brain damage tended to increase, while those that worsen injury tended to decrease. Because GHRP-6 was given together with EGF, its individual effect can't be separated out. This was an animal study describing molecular changes; the results support the idea of neuroprotection but do not prove a benefit in people.
Reported protocols (with caveats)
| USE | ROUTE | COMMON DOSE | FREQUENCY | TYPICAL CYCLE |
|---|---|---|---|---|
| GH stimulation (community-reported) | SC injection (fasted state) | 100–300 mcg | 1–3× daily | 8–12 weeks |
| Combination with GHRH analogue (community-reported) | SC injection | 100 mcg GHRP-6 | 2× daily with sermorelin or CJC-1295 | 8–12 weeks |
Frequently asked questions
- What are the documented side effects of GHRP-6?
- The most consistently reported effect in GHRP-6 research subjects is a substantial, transient increase in appetite — a direct pharmacological consequence of ghrelin receptor (GHS-R1a) activation. Transient elevation of cortisol and prolactin has also been observed in pharmacokinetic studies (Cabrales et al., 2013; PMID 23099431). Hypoglycaemia and IGF-1-mediated effects with prolonged use are theoretical concerns that have not been formally characterised in human therapeutic trials. Injection-site reactions are reported in community accounts. The full risk profile in the context of self-administered community protocols is unknown.
- How does GHRP-6 differ from GHRH-based peptides like sermorelin?
- GHRP-6 activates the ghrelin receptor (GHS-R1a) rather than the GHRH receptor (GHRHR). These are distinct receptor systems that operate through different intracellular signalling pathways. GHRH analogues and GHS-R1a agonists are synergistic rather than redundant — simultaneous activation of both pathways produces substantially more GH release than either alone. A further practical distinction is that GHRP-6 also activates the appetite-stimulating arm of ghrelin signalling, which GHRH analogues do not.
- Is there human clinical evidence for GHRP-6?
- Human evidence establishes that GHRP-6 stimulates GH release in a dose-dependent manner and produces the documented hormonal side effects (cortisol, prolactin elevation, appetite stimulation). What does not exist is a controlled trial demonstrating therapeutic benefit — in body composition, recovery, or any other community-relevant endpoint — from sustained community-style administration. Pharmacokinetic evidence does not substitute for efficacy trial evidence.
- Is GHRP-6 legal to buy or use?
- GHRP-6 is not approved for human therapeutic use in the United States, Australia, Canada, the UK, or the EU. In most jurisdictions it is sold as a research chemical. Regulatory status varies by country and is subject to change; verify current status with a qualified legal or clinical professional.
- Why does GHRP-6 cause such strong hunger?
- GHRP-6 activates the ghrelin receptor (GHS-R1a), which mediates appetite stimulation via hypothalamic circuits — the same pathway through which endogenous ghrelin signals pre-meal hunger. This orexigenic effect is intrinsic to GHS-R1a agonism and is documented in controlled human studies. Community members frequently note this as the compound's most immediately noticeable effect. It is one reason some community protocols favour ipamorelin or GHRP-2, which are reported to produce less appetite stimulation at comparable GH-stimulating doses.